Avecho Biotechnology Limited (OEZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avecho Biotechnology Limited (OEZ) has a cash flow conversion efficiency ratio of -0.334x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-808.80K ≈ $-945.58K USD) by net assets (€2.42 Million ≈ $2.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Avecho Biotechnology Limited to measure how much of total assets are equity-financed.
Avecho Biotechnology Limited - Cash Flow Conversion Efficiency Trend (2013–2022)
This chart illustrates how Avecho Biotechnology Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Avecho Biotechnology Limited to evaluate the quality of earnings relative to operating cash generation.
Avecho Biotechnology Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avecho Biotechnology Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gurktaler AG ST
VI:GAGS
|
-0.006x |
|
Duc Long Gia Lai Group JSC
VN:DLG
|
-0.523x |
|
Acrinova AB Series B
ST:ACRI-B
|
0.092x |
|
Romcarbon Sa B
RO:ROCE
|
0.005x |
|
The Steel Public Company Limited
BK:THE
|
0.156x |
|
WOOJUNG BIO Inc
KQ:215380
|
-0.033x |
|
rYojbaba Co., Ltd. Common Shares
NASDAQ:RYOJ
|
0.000x |
|
Flexiroam Ltd
AU:FRX
|
-0.898x |
Annual Cash Flow Conversion Efficiency for Avecho Biotechnology Limited (2013–2022)
The table below shows the annual cash flow conversion efficiency of Avecho Biotechnology Limited from 2013 to 2022. For the full company profile with market capitalisation and key ratios, see Avecho Biotechnology Limited (OEZ) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2022-12-31 | €2.42 Million ≈ $2.83 Million |
€-1.67 Million ≈ $-1.95 Million |
-0.687x | -0.54% |
| 2021-12-31 | €4.54 Million ≈ $5.30 Million |
€-3.10 Million ≈ $-3.62 Million |
-0.683x | -27.33% |
| 2020-12-31 | €2.65 Million ≈ $3.10 Million |
€-1.42 Million ≈ $-1.66 Million |
-0.536x | -316.76% |
| 2019-12-31 | €4.76 Million ≈ $5.56 Million |
€1.18 Million ≈ $1.38 Million |
0.247x | +144.12% |
| 2018-12-31 | €3.90 Million ≈ $4.56 Million |
€-2.19 Million ≈ $-2.56 Million |
-0.561x | +44.06% |
| 2017-12-31 | €6.40 Million ≈ $7.49 Million |
€-6.42 Million ≈ $-7.51 Million |
-1.003x | -82.13% |
| 2016-12-31 | €11.65 Million ≈ $13.62 Million |
€-6.41 Million ≈ $-7.50 Million |
-0.551x | -82.96% |
| 2015-12-31 | €28.93 Million ≈ $33.82 Million |
€-8.71 Million ≈ $-10.18 Million |
-0.301x | -118.93% |
| 2014-12-31 | €49.03 Million ≈ $57.32 Million |
€-6.74 Million ≈ $-7.88 Million |
-0.137x | +36.70% |
| 2013-12-31 | €39.50 Million ≈ $46.18 Million |
€-8.58 Million ≈ $-10.03 Million |
-0.217x | -- |
About Avecho Biotechnology Limited
Avecho Biotechnology Limited, a biotechnology company, develops and commercializes human and animal health products using its proprietary drug delivery system, tocopherol phosphate mixture (TPM) in Australia, Switzerland, France, and India. It operates through Production and Human Health segments. The company manufactures and sells TPM and Vital ET products for use in drug delivery and cosmetic f… Read more